About the Company
Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the company knows the need for treatment options is urgent - that is why its global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.
Employees
262
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TVTX News
Analyst Ratings For Travere Therapeutics
Analysts have recently evaluated Travere Therapeutics and provided 12-month price targets. The average target is $18.38, ...
Travere’s Filspari safari bags full FDA nod in IgAN; REMS next
With full approval from the U.S. FDA in hand for Travere Therapeutics Inc.’s Filspari (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) who are at risk of ...
Despite trial scare, Travere's Filspari gains full FDA nod in kidney disease showdown with Novartis
A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...
Travere Therapeutics Shares Rise on Full FDA Nod for Kidney Drug
Shares of Travere Therapeutics moved higher after the biopharmaceutical company said it won full Food and Drug Administration approval of its kidney-disease drug Filspari. Travere shares were recently ...
Travere Therapeutics Inc (TVTX) Stock Sees Market Value Hit $686.88 million: What Are the Implications?
On Friday, Travere Therapeutics Inc (TVTX) stock saw a modest uptick, ending the day at $8.98 which represents a slight increase of $0.41 or 4.78% from the prior close of $8.57. The volume of shares ...
TVTX Travere Therapeutics, Inc.
View Travere Therapeutics, Inc. (TVTX) current and estimated P/E ratio data provided by Seeking Alpha.
Biotech Stocks Facing FDA Decision In September 2024
As September unfolds, let us review some of the regulatory news that made headlines last month and look ahead to what this month has ...
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present two posters in classical homocystinuria (HCU) at the Society for ...
Travere Therapeutics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TVTX Travere Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Travere Therapeutics Inc (TVTX)
Travere Therapeutics (NASDAQ: TVTX) has reported substantial growth in the second quarter of 2024, driven by the increasing demand for FILSPARI, its therapy for IgA nephropathy... ByInvesting.com • 05 ...
Loading the latest forecasts...